CN106518859B - Thiazole derivative and its preparation method and application - Google Patents
Thiazole derivative and its preparation method and application Download PDFInfo
- Publication number
- CN106518859B CN106518859B CN201610928140.4A CN201610928140A CN106518859B CN 106518859 B CN106518859 B CN 106518859B CN 201610928140 A CN201610928140 A CN 201610928140A CN 106518859 B CN106518859 B CN 106518859B
- Authority
- CN
- China
- Prior art keywords
- compound
- general formula
- pharmaceutical composition
- thiazole
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 150000007979 thiazole derivatives Chemical class 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 10
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 4
- -1 4- chlorphenyl Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 125000003368 amide group Chemical group 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000001055 chewing effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- RABBMOYULJIAFU-UHFFFAOYSA-N 1h-pyrrole;thiophene Chemical class C=1C=CNC=1.C=1C=CSC=1 RABBMOYULJIAFU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Chemical class 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 3
- 229940122388 Thrombin inhibitor Drugs 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Chemical class 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 2
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 2
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108700032141 ganirelix Proteins 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical class ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- VXJPCEOTZNHHOA-UHFFFAOYSA-N [K].OC Chemical compound [K].OC VXJPCEOTZNHHOA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940047562 eliquis Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229950010535 razaxaban Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the new thiazole derivatives and its pharmaceutically acceptable salt with logical formula (I) structure, wherein each group definition is as used in the description.The invention further relates to the preparation method of the compound, containing they pharmaceutical composition and its as bioactive substance be used to prepare prevention and/or treat thrombotic disease drug purposes.
Description
Technical field
The present invention relates to anticoagulant fields, specifically the present invention relates to new thiazole derivative, preparation method and its
It is being used to prepare prevention and/or is treating the purposes of thrombotic disease drug or pharmaceutical composition.
Background technique
In the angiocarpy of people, blood occurs certain visible components precipitations, agglutination in solidification or blood and forms solid mass
Process, referred to as thrombosis, being formed by solid mass is thrombus.Blood clotting was a kind of protection machine of organism originally
System, however, triggering abnormal coagulation process, blood in the case where blood flow anomalies, blood vessel change in wall or coagulation factor exception
Liquid can form thrombus or embolism, so as to cause thromboembolisms such as myocardial infarction, apoplexy, deep vein thrombosis or pulmonary embolism
Property disease.Thrombotic disease is the disease that most serious is endangered in cardiovascular disease, is the first killer of human health.
The drug of existing antithrombotic embolism class diseases is divided into antiplatelet drug, anticoagulation medicine and fibrinolytic drug
Object.Wherein, anticoagulation medicine mainly has thrombin inhibitor, vitamin K antagon and Xa factor inhibitor.With heparin and low point
Sub- heparin is that the thrombin inhibitor of representative has the disadvantages of taking orally invalid, non-selective inhibition and High risk of bleeding.With magnificent method
Although the vitamin K antagon that Lin Wei is represented can take orally, therapeutic index is narrow, big with food drug interaction, individual
Dose difference is also bigger.
Studies have shown that Xa factor is the best target of development of new anticoagulant, have razaxaban, Eliquis at present
It is listed with edoxaban.The direct inhibition of Xa factor can generate efficient blood coagulation resisting function, and without thrombin inhibitor
Side effect.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of completely new thiazole derivative, which has anticoagulant work
With, can be used in prevent and/or treat thrombotic disease.
In order to solve the above technical problems, there is the structure as shown in formula (I) the present invention provides a kind of compound:
Or its pharmaceutically acceptable salt, in which:
R1Selected from fluorine, chlorine, bromine；
R2Selected from hydrogen, fluorine, chlorine, methyl.
Preferably, the compound of the present invention is selected from following compounds:
I-1:N- (4- chlorphenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- first
Amide；
I-2:N- (4- bromophenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- first
Amide；
I-3:N- (4- bromophenyl) -2- ((the fluoro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -
4- formamide；
I-4:N- (4- fluorophenyl) -2- ((2- methyl -4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiophene
Azoles -4- formamide；
I-5:N- (4- chlorphenyl) 2- ((the chloro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -
4- formamide；
Or its pharmaceutically acceptable salt.
The compound pharmaceutically acceptable salt of logical formula (I) of the present invention, both officinal salt, was logical formula (I) structure
Compound and various inorganic acids (including but not limited to, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid) or organic acid (including
But it is not limited to, such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, malic acid, citric acid, oxalic acid, fumaric acid, maleic acid, amino acid, first
Sulfonic acid, ethanesulfonic acid, benzene sulfonic acid etc.) generate salt.
The compound pharmaceutically acceptable salt of logical formula (I) of the present invention, both officinal salt, can also be logical formula (I)
The compound of structure and various alkaline matters (hydroxide, carbonate or the bicarbonate of such as alkali or alkaline earth metal, including
But be not limited to: sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate etc.) generate salt, such as corresponding sodium salt, sylvite or calcium salt
Deng.Nontoxic organic base such as methylamine, triethylamine or meglumine etc. can also be used and generate salt.
The compound of the present invention is synthesized by following steps:
Wherein: R1Selected from fluorine, chlorine, bromine；R2Selected from hydrogen, fluorine, chlorine, methyl；
The compound of general formula (VIII) reacts the compound for preparing general formula (VII) with chloracetyl chloride in a solvent；General formula (VII)
Compound prepares the compound of general formula (VI) with potassium rhodanide or sodium sulfocyanate reaction in a solvent；The compound of general formula (VI) with
The compound of general formula (V) reacts the compound for generating general formula (IV) in a solvent；The compound of general formula (IV) is logical through hydrolysis preparation
The compound of formula (III)；The compound of general formula (III) reacts the change for generating general formula (I) with the compound of general formula (II) in a solvent
Close object.
Wherein, the compound of general formula (II), (V) and (VIII) can be obtained by commercial sources, such as lark prestige, Ah method's Sha's public affairs
Department, can also be prepared by known method.
Wherein, solvent used in preparation method refers to inert organic solvent at reaction conditions, including but not limited to,
Ether, such as tetrahydrofuran, ether, glycol dimethyl ether；Halogenated hydrocarbons, such as 1,2- dichloroethanes, methylene chloride, chloroform, four
Chlorination carbon etc.；Alcohol, such as methanol, ethyl alcohol, isopropanol, the tert-butyl alcohol；Hydrocarbon, such as benzene,toluene,xylene, hexane, hexamethylene；Its
It, such as dimethyl sulfoxide, dimethylformamide, acetonitrile, pyridine, water, hexamethylphosphoric triamide.Solvent can also be above-mentioned molten
The mixture of agent.
Wherein, in preparation method, can also add in the reaction of synthesis general formula VII, general formula IV, general formula III and general formula I
Entering alkali, suitable alkali can be conventional inorganic base or organic base in reaction, including but not limited to, the hydroxide of alkali metal,
Such as potassium hydroxide or sodium hydroxide；The carbonate of alkali metal, such as potassium carbonate or sodium carbonate；Alkoxide, such as sodium methoxide, methanol
Potassium, sodium ethoxide, potassium ethoxide or potassium tert-butoxide etc.；Amine, such as methylamine, hydrazine hydrate, triethylamine, diisopropylethylamine, pyridine.Alkali
It is 1~5 mole, preferably 1~2 mole that dosage, which is based on 1 molar reactive substrate,.
Reaction can carry out at various pressures, such as decompression, normal pressure or pressurization, preferably carry out under normal pressure.
Reaction generally -78 DEG C to reflux temperature at a temperature of carry out, preferably 0 DEG C to reflux temperature of range carries out.
The compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention can play anticoagulation by inhibition Xa,
Therefore it can be used for preparing prevention and/or treat the drug or pharmaceutical composition of thrombotic disease.Wherein, thromboembolia type disease
The concept of disease is known to those skilled in the art.
In addition, the compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention can also be used to prevent to solidify in vitro, such as
For preventing the solidification of the biological sample containing Xa factor.
The compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention, can with it is one or more pharmaceutically acceptable
Carrier, excipient or diluent pharmaceutical composition is made jointly.Solid orally ingestible, liquid can be made in the pharmaceutical composition
The dosage forms such as oral preparation or injection.
The solid orally ingestible includes: tablet, dispersible tablet, enteric coatel tablets, chewable tablets, oral disintegrating tablet, capsule, granule.It adopts
Use lactose or starch as the diluent of the solid orally ingestible；Using gelatin, methylcellulose, hydroxypropyl methylcellulose, gather
Vinylpyrrolidone, starch slurry etc. are used as adhesive；Use starch, sodium carboxymethylcellulose, carboxyrnethyl starch sodium, low-substituted hydroxypropyl
Methylcellulose, crospovidone, microcrystalline cellulose are as disintegrating agent；Use talcum powder, micro- part of silica gel, tristerin, hard
Resin acid calcium or magnesium etc. are used as antiadhesives and lubricant.
The preparation method of the solid orally ingestible is the following steps are included: by active constituent and carrier and disintegration additive
Then composition mixture makes the aqueous solution of the mixture and adhesive, alcohol or aqueous alcohol solution are in suitable equipment
Wet process or dry granulation are carried out, dry particle is then added other disintegrating agents, lubricant and antiplastering aid and system appropriate is made
Agent.
The liquid oral medicine includes syrup and oral solution.
Series compound of the invention can also be administered by non-bowel form.Optimizing injection administration, including injection
Water needle, injection powder needle and primary infusion.
Series compound of the invention is effective in comparatively wide measures range, such as the dosage taken daily is 1
Within the scope of~1000mg/ people, it can divide primary or be administered for several times.The dosage for actually taking the compounds of this invention should be by doctor's root
It is determined according to related situation, these situations include the physical condition of patient, the administration route of patient, the age, weight, right
Individual reaction and the severity of symptom of drug etc..
Specific embodiment
The present invention will be further explained with reference to the examples below, and the examples are merely illustrative, is in no way intended to it
It limits the scope of the invention in any way.
Embodiment 1:
Compound I-1:N- (4- chlorphenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiophene
Azoles -4- formamide；
5.00g paraiodoaniline (compound VIII -1) is added in reaction flask, 25ml tetrahydrofuran, 4.60g triethylamine, 0.1g's
DMAP (4-dimethylaminopyridine), agitation and dropping 3.86g chloracetyl chloride, adds 25-35 insulated and stirred 2 hours, heats up 50 DEG C, protects
Solvent to the greatest extent is steamed in temperature reaction 2h, decompression, and 30ml water is added, and agitation and filtration is dry, obtains 5.6g gray solid, is compound VII -1.
5.0g compound VII -1,1.7g sodium sulfocyanate, 0.5g tetrabutylammonium iodide are put into 50ml acetonitrile, stirred
It is warming up to reflux, insulated and stirred, contact plate controls fully reacting, and solvent to the greatest extent is steamed in decompression, and 250ml water agitation and filtration is added, and filter cake is used
It washes (20ml × 2), it is dry, 3.60g gray solid is obtained, is compound VI -1.
Addition 3.2g compound VI -1 in reaction flask, 2.4g compound V, 1g cuprous iodide, 0.5g8- oxyquinoline,
1.4g potassium carbonate, 25mlDMF (dimethylformamide), nitrogen protection, stirring are warming up to reflux, and insulated and stirred, contact plate control is instead
It should be complete.Solvent to the greatest extent is steamed in decompression, and 30ml water is added, and ethyl acetate extracts (100ml × 3), merges organic phase, saturated sodium chloride water
Solution is washed (15ml × 1), and anhydrous sodium sulfate is dry, and silica gel column chromatography obtains 2.6g pale solid, is compounds Ⅳ -1.
2.5g compounds Ⅳ -1,20ml dehydrated alcohol, the lithium hydroxide that 20ml mass concentration is 15% are added in reaction flask
Aqueous solution is stirred at room temperature, and contact plate controls fully reacting.Ethyl alcohol to the greatest extent, 0-10 DEG C of 20% (mass concentration) acetic acid water of dropwise addition are steamed in decompression
Solution adjusts pH to 6-7, solid occurs, filters, and washes (25ml × 3), dry, obtains 1.6g pale solid, is compound III-
1。
In reaction flask be added 0.5g compound III -1,0.3g compound ii -1,0.5gTBTU (O- benzotriazole-N, N,
N', N'- tetramethylurea tetrafluoro boric acid), 0.5g triethylamine, 10mlDMF, nitrogen protection is stirred at room temperature, and contact plate control has been reacted
Entirely.100ml water is added in reaction solution, and ethyl acetate extracts (100ml × 3), merges organic phase, and saturated sodium-chloride water solution is washed
(15ml × 1), anhydrous sodium sulfate is dry, and silica gel column chromatography obtains 0.15g off-white powder, is chemical compounds I -1.
1H-NMR(DMSO-d6), δ (ppm): 4.012 (s, 2H), 6.507 (d, 2H), 6.679 (s, 1H), 7.023 (d,
2H),7.456(d,2H),7.738(d,2H),8.389(s,1H),10.643(s,1H),11.452(s,1H)。
Embodiment 2:
Compound I-2:N- (4- bromophenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiophene
Azoles -4- formamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound II-2 is different, specifically such as
Under,
1H-NMR(DMSO-d6), δ (ppm): 4.015 (s, 2H), 6.510 (d, 2H), 6.682 (s, 1H), 7.126 (d,
2H),7.558(d,2H),7.748(d,2H),8.688(s,1H),10.743(s,1H),11.482(s,1H)。
Embodiment 3:
Compound I-3:N- (4- bromophenyl) -2- ((the fluoro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amine
Base) thiazole -4-carboxamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound VIII-3 and II-3 are not
It is together, specific as follows,
1H-NMR(DMSO-d6), δ (ppm): 4.108 (s, 2H), 6.686 (s, 1H), 7.005 (d, 1H), 7.146 (d,
1H),7.346-7.568(m,5H),8.480(s,1H),10.446(s,1H),11.382(s,1H)。
Embodiment 4:
Compound I-4:N- (4- bromophenyl) -2- ((2- methyl -4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amine
Base) thiazole -4-carboxamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound VIII-4 and II-4 are not
It is together, specific as follows,
1H-NMR(DMSO-d6), δ (ppm): 2.140 (s, 3H), 4.106 (s, 2H), 6.510 (d, 1H), 6.686 (s,
1H),6.935(d,1H),7.226(d,2H),7.468-7.612(m,3H),8.228(s,1H),10.246(s,1H),11.382
(s,1H)。
Embodiment 5:
Compound I-5:N- (4- chlorphenyl) 2- ((the chloro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido)
Thiazole -4-carboxamide；
The present embodiment uses synthetic method same as Example 1, the difference is that compound VIII-5 is different, specifically
It is as follows,
1H-NMR(DMSO-d6), δ (ppm): 4.108 (s, 2H), 6.686 (s, 1H), 7.005 (d, 1H), 7.146 (d,
1H),7.426(d,2H),7.568-7.768(m,3H),8.690(s,1H),10.543(s,1H),11.682(s,1H)。
Embodiment 6
The compound or pharmaceutically acceptable salt thereof of logical formula (I) structure of the invention to the inhibiting effect of factor Xa in the following manner
Measurement:
Untested compound is dissolved in DMSO by various concentration, and (public purchased from HYPHEN BioMed with the Xa factor of the mankind
Department) and Tris buffer 37 DEG C warm bath 2 minutes.Then chromogenic substrate (being purchased from HYPHEN BioMed company), 37 DEG C of temperature are added
It is excited and is measured in 405nm with microplate reader after bath 50 minutes.It is compared with pure DMSO (dimethyl sulfoxide).Test substances will be contained
Test mixture excitation and the control mixture without test substances comparison, and IC is calculated by these data50Value,
It the results are shown in Table 1.
1 compound of table inhibits the active IC of FXa50
| Embodiment | 1 | 2 | 3 | 4 |
| Compound | I-1 | I-2 | I-3 | I-4 |
| IC50/nM | 30 | 25 | 42 | 48 |
In order to more fully explain implementation of the invention, following example of formulations are provided.These embodiments be only explain,
It is not intended to limit the scope of the invention.Preparation can be using any one compound in the present invention as active constituent.
Embodiment 7
The preparation of tablet:
| Prescription | 1000 dosages |
| Compound I-1 made from embodiment 1 | 80g |
| Microcrystalline cellulose | 30g |
| Pregelatinized starch | 40g |
| Lactose | 120g |
| Hydroxypropyl methylcellulose | 8g |
| Sodium carboxymethyl starch | 12g |
| Magnesium stearate | qs |
| Silica | qs |
Technique: active constituent auxiliary material is sieved with 100 mesh sieve respectively, and (half carboxymethyl forms sediment the main ingredient and auxiliary material for weighing recipe quantity
Powder sodium) it is sufficiently mixed, hydroxypropyl methylcellulose aqueous solution softwood processed in right amount is added, crosses 24 meshes, wet granular is made and is dried in 50-60 DEG C
About 2-3 hours dry in case, by remaining sodium carboxymethyl starch, magnesium stearate and silica are uniformly mixed with particle, whole grain, are surveyed
Intermediates content is determined, with special-shaped stamping.
Embodiment 8
The preparation of capsule:
| Prescription | 1000 capsule dosages |
| Compound I-3 made from embodiment 3 | 100g |
| Microcrystalline cellulose | 20g |
| Lactose | 120g |
| Low-substituted hydroxypropyl cellulose | 6g |
| 10% starch slurry | qs |
| Magnesium stearate | qs |
Technique: active constituent auxiliary material is sieved with 100 mesh sieve respectively, and the main ingredient and auxiliary material for weighing recipe quantity are sufficiently mixed, and is added
Povidone aqueous solution in right amount dry about 2-3 hours in 50-60 DEG C of baking oven by softwood processed, excessively 20 meshes, obtained wet granular, will be stearic
Sour magnesium is uniformly mixed with particle, whole grain, measures intermediates content, filling with No. 2 capsules.
Claims (10)
1. a kind of compound has the structure as shown in formula (I):
Or its pharmaceutically acceptable salt, in which:
R1Selected from fluorine, chlorine, bromine；
R2Selected from hydrogen, fluorine, chlorine, methyl.
2. compound as described in claim 1 is selected from following compounds:
N- (4- chlorphenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4-carboxamide；
N- (4- bromophenyl) -2- ((4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4-carboxamide；
N- (4- bromophenyl) -2- ((the fluoro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- formyl
Amine；
N- (4- fluorophenyl) -2- ((2- methyl -4- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4- formyl
Amine；
N- (4- chlorphenyl) 2- ((the chloro- 4- of 2- (5- oxo -2- thiocarbamoyl imidazole alkane -1- base) phenyl) amido) thiazole -4-carboxamide；
Or its pharmaceutically acceptable salt.
3. the compound as described in any one of claims 1 or 2, wherein the pharmaceutically acceptable salt includes logical formula (I)
The salt that the compound and inorganic acid or organic acid of structure generate.
4. the preparation method of compound described in any one of claims 1 or 2, comprising the following steps:
Wherein: R1Selected from fluorine, chlorine, bromine；R2Selected from hydrogen, fluorine, chlorine, methyl；
The compound of general formula (VIII) reacts the compound for preparing general formula (VII) with chloracetyl chloride in a solvent；The chemical combination of general formula (VII)
Object prepares the compound of general formula (VI) with potassium rhodanide or sodium sulfocyanate reaction in a solvent；The compound and general formula of general formula (VI)
(V) compound reacts the compound for generating general formula (IV) in a solvent；The compound of general formula (IV) prepares general formula through hydrolysis
(III) compound；The compound of general formula (III) reacts the chemical combination for generating general formula (I) with the compound of general formula (II) in a solvent
Object.
5. compound described in any one of claims 1 or 2 is being used to prepare prevention and/or treatment thrombotic disease medicine
The purposes of object or pharmaceutical composition.
6. a kind of pharmaceutical composition, wherein contain at least one described in any item compounds of claims 1 or 2 as effectively at
Point, and contain one or more pharmaceutical acceptable carrier, diluent or excipient.
7. pharmaceutical composition as claimed in claim 6, wherein the pharmaceutical composition is solid orally ingestible, liquid port
Formulation or injection.
8. pharmaceutical composition as claimed in claim 7, wherein the solid orally ingestible is dispersible tablet, enteric coatel tablets, chewing
Piece, oral disintegrating tablet, capsule or granule.
9. pharmaceutical composition as claimed in claim 7, wherein the liquid oral medicine is syrup or oral solution.
10. pharmaceutical composition as claimed in claim 7, wherein the injection is injection water needle, injection powder needle or small
Infusion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610672153 | 2016-08-15 | ||
| CN201610672153X | 2016-08-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106518859A CN106518859A (en) | 2017-03-22 |
| CN106518859B true CN106518859B (en) | 2019-01-18 |
Family
ID=58293137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610928140.4A Active CN106518859B (en) | 2016-08-15 | 2016-10-31 | Thiazole derivative and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106518859B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101967145A (en) * | 2010-09-09 | 2011-02-09 | 华东理工大学 | Method for preparing antithrombotic medicament apixaban |
| CN102702186A (en) * | 2012-06-20 | 2012-10-03 | 安润医药科技（苏州）有限公司 | Synthesis method of rivaroxaban |
| CN103342704A (en) * | 2013-07-25 | 2013-10-09 | 甘肃皓天化学科技有限公司 | Preparation method of Apixaban as anti-thrombotic drug |
| CN103562183A (en) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | Benzoic acid salt of otamixaban |
-
2016
- 2016-10-31 CN CN201610928140.4A patent/CN106518859B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101967145A (en) * | 2010-09-09 | 2011-02-09 | 华东理工大学 | Method for preparing antithrombotic medicament apixaban |
| CN103562183A (en) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | Benzoic acid salt of otamixaban |
| CN102702186A (en) * | 2012-06-20 | 2012-10-03 | 安润医药科技（苏州）有限公司 | Synthesis method of rivaroxaban |
| CN103342704A (en) * | 2013-07-25 | 2013-10-09 | 甘肃皓天化学科技有限公司 | Preparation method of Apixaban as anti-thrombotic drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106518859A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102464658B (en) | Oxazolidinone derivative and preparation method and application thereof | |
| CN101260112B (en) | Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof | |
| JP2019135258A (en) | CRYSTALLINE FORMS OF FACTOR Xa INHIBITOR | |
| KR20080003599A (en) | Gentiate salts of pyrrolopyrimidinone derivatives and preparation method thereof | |
| CN102442965B (en) | PAR-1 (protease-activated receptor-1) antagonists for treating thrombotic diseases, as well as preparation and application thereof | |
| JP7264999B2 (en) | Salt formed by 2-(1-acyloxy-N-pentyl)benzoic acid and basic amino acid or aminoguanidine, production method and use thereof | |
| JP2012512186A (en) | Amidothiazole derivatives, process for their production and use | |
| CN104470893A (en) | Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives | |
| CN103524559A (en) | Ester derivatives of multi-substituted 4-methylamino-benzamidine as well as preparation method and application of ester derivatives | |
| CN106518859B (en) | Thiazole derivative and its preparation method and application | |
| WO2015192672A1 (en) | Benzofuran derivative, preparation method therefor, and application thereof | |
| CN106565698B (en) | Substituted thiazole analog derivative and its preparation method and application | |
| HUT70174A (en) | New 3-phenyl-sulphonyl-3,7-diazabicyclo [3.3.1] nonane compounds and pharmaceutical compounds containing the same | |
| CA2990747C (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
| KR20210081368A (en) | Potassium monohydrate salt of thienopyridone derivative and method for preparing same | |
| RU2597423C2 (en) | Benzoate salt of otamixaban | |
| KR100936278B1 (en) | A composition for preventing and treating cancer containing pyrimidine derivatives that inhibit the activity of protein phosphatase or pharmaceutically acceptable salts thereof as an active ingredient | |
| CN102796040B (en) | 1,4-disubstituted piperazine derivatives and their preparation method and use | |
| JP2001151742A (en) | Anilide derivative and antiarrhythmic agent containing the same | |
| KR20140000717A (en) | Novel anti-platelet compound addition salt | |
| CN102532107B (en) | 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof | |
| CN102796093B (en) | Thiomorpholine-containing pyrrole derivatives and their preparation method and use | |
| CN103664930B (en) | One class is containing compound, the Preparation Method And The Use of thiazole structure | |
| CN116535361A (en) | Substituted hydroxypyrimidine xanthine oxidase inhibitor and its preparation method and pharmaceutical use | |
| JPS59231057A (en) | Carboxylic acid amide compound and its derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |